- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01484210
Single Dose Study of the Fluticasone/Salmeterol (500/50 μg) Administered With Elpenhaler® Versus Diskus®
Phase III Therapeutic Evaluation Study Comparing the Efficacy and Safety of the Fluticasone/Salmeterol (500/50 μg) Combination Administered With Elpenhaler® (Rolenium®) Versus the Innovative One (Seretide Diskus®) in Patients With Asthma.
The aim of this study is to establish the therapeutic equivalence between the test (Fluticasone/Salmeterol administered with Elpenhaler®, Rolenium®) and the reference formulation (Seretide®, administered with Diskus®), both containing 500/50μg of the Fluticasone/Salmeterol combination.
The study will be conducted in a randomized, double-blind, double-dummy, 2x2 crossover fashion.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In case of inhaled products, it is not possible to follow the classic scheme, based on similarity of plasma concentration-time behavior of parent drug in assessing bioequivalence.
For this reason, a pharmacodynamic study was designed in order to assess the therapeutic equivalence of the new formulation of Fluticasone/Salmeterol with the innovative one. The test and reference Fluticasone/Salmeterol formulations will be compared in terms of their bronchodilator effects in lung function. Forced Expiratory Volume in 1 second (FEV1) will be the primary efficacy measure and will be measured in such a way that a similar time-dependent increase in pulmonary function can be demonstrated for both Fluticasone/Salmeterol formulations in patients with asthma. In terms of safety comparison, repeated measurements of adverse events, vital signs, heart rate, blood hematology and biochemistry as well as ECG changes will enable the establishment of the similar safety profile of the test and reference Fluticasone/Salmeterol combinations.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Nove Mesto, Czechia, 337 01
- Pneumology and allergology surgery Voldusska 750
-
Prague, Czechia, 1536
- Pneumology surgery Hostinskeho 1536
-
Prague, Czechia, 19800
- Pneumology surgery Generala Janouska 902/17
-
-
Drahovice
-
Karlovy Vary, Drahovice, Czechia, 56001
- Pneumology surgery Vitezna 201/31
-
-
Zizkov
-
Kutna Hora, Zizkov, Czechia
- Pneumology surgery Vojtesska 237
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- age 18-65 years,
- diagnosis of asthma of 6 months,
- FEV1 ≥ 50% and ≤ 80% predicted,
- reversibility of at least 12%,
- stable asthma for at least 4 weeks,
- inhaled steroids (ICS) at a stable dose within the previous 30 days,
- PIF 30 - 90 lt/min and
- informed consent.
Exclusion Criteria:
- history of other pulmonary disease,
- asthma exacerbation or respiratory infection within the previous 4 weeks,
- hospitalization for acute asthmatic symptoms requiring parenteral steroids or oral steroid dose increase, within the previous 30 days,
- heavy smokers,
- change of asthma medication within the previous 4 weeks,
- seasonal asthma alone,
- history of severe heart disease,
- pregnancy or lactation,
- use of a β-blocker, of a NSAID or an antiallergic/antihistaminic medication within 2 weeks prior to screening visit.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Elpenhaler Active - Diskus Placebo
Patients on treatment with both devices, Elpenhaler and Diskus, first active substance, second placebo.
|
randomized, double-blind, double-dummy, 2-way crossover, single dose study, comparing the efficacy and safety of the Fluticasone/Salmeterol (500/50 μg) combination administered with Elpenhaler® (Rolenium®) versus the innovative one (Seretide Diskus®) in patients with asthma.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The primary variable will be the 12-hour average FEV1 [area under the FEV1 versus time curve divided by 12 (FEV1 AUC0-12/12)].
Time Frame: 0 (baseline), Visit 1 (3-7 days), Visit 2 (3-7 days), Telephone Contact Follow up (3-7 days)
|
To establish the therapeutic equivalence between the Fluticasone/Salmeterol combination administered with Elpenhaler® (Rolenium®) and the innovative one (Seretide Diskus®) in terms of their bronchodilator effect in lung function.
|
0 (baseline), Visit 1 (3-7 days), Visit 2 (3-7 days), Telephone Contact Follow up (3-7 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The FEV1 values over time for the 12-hour observation period
Time Frame: 0 (baseline), Visit 1 (3-7 days), Visit 2 (3-7 days), Telephone Contact Follow up (3-7 days)
|
To compare the efficacy and safety profile of the two Fluticasone/Salmeterol formulations in patients with asthma.
|
0 (baseline), Visit 1 (3-7 days), Visit 2 (3-7 days), Telephone Contact Follow up (3-7 days)
|
Time to peak FEV1
Time Frame: 0 (baseline), Visit 1 (3-7 days), Visit 2 (3-7 days), Telephone Contact Follow up (3-7 days)
|
To compare the effiacy and safety profile of the two Fluticasone/Salmeterol formulations in patients with asthma
|
0 (baseline), Visit 1 (3-7 days), Visit 2 (3-7 days), Telephone Contact Follow up (3-7 days)
|
Time to peak FEV1 maximum value
Time Frame: same as FEV1
|
same as FEV1
|
same as FEV1
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: A Dindos, MD, Pneumology Surgery, Kojeticka 1021, 27711 Neratovicae
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2007-FLUSAL-EL-02
- Sponsor ID (Other Identifier: FLUSAL-02)
- 2007-006670-29 (EudraCT Number)
- Sponsor FLUSAL-02 (Other Grant/Funding Number: Elpen Pharmaceutical Co Inc)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Johann Wolfgang Goethe University HospitalCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Universita di VeronaCompleted
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
Clinical Trials on Elpenhaler active - Diskus placebo
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited States
-
University of Nove de JulhoFundação de Amparo à Pesquisa do Estado de São PauloCompletedExcessive Physical Exercise, UnspecifiedBrazil
-
Novozymes A/SAnalyze & RealizeNot yet recruiting
-
Vanda PharmaceuticalsCompleted
-
SIMR (Australia) Biotech Pty Ltd.CompletedPeripheral Neuropathic PainAustralia
-
Universidade Federal de Sao CarlosFundação de Amparo à Pesquisa do Estado de São PauloCompleted
-
University of Sao Paulo General HospitalCompletedSpinal Cord InjuriesBrazil
-
Tel Aviv UniversityWalter Reed Army Institute of Research (WRAIR); Medical Corps, Israel Defense...Completed
-
Hospital Ambroise Paré ParisCompletedLumbar RadiculopathyFrance